In preclinical studies, elevated circulating levels of FGF2 have been linked to breast cancer development through the activation of oncogenic signalling pathways, including MAPK/ERK, cMYC and PI3K/AKT/mTOR. This evidence concerns the gene MTOR and breast carcinoma.